• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Kyowa Kirin (TSE:4151) Reports Strong Half Year Earnings, Is The Valuation Still Compelling?

    Simply Wall St·08/13/2026 12:29:34
    Listen to the news

    Why Kyowa Kirin’s Latest Earnings Matter For Shareholders

    Kyowa Kirin (TSE:4151) drew fresh attention after reporting half year earnings to June 30, 2026, with sales of ¥263,629 million and net income of ¥30,618 million, including basic EPS of ¥58.48 from continuing operations.

    See our latest analysis for Kyowa Kirin.

    The latest earnings release has come alongside a 9.81% 90 day share price return for Kyowa Kirin, while the 1 year total shareholder return is 1.60%. This suggests that momentum has picked up recently compared with longer term performance.

    If these results have you looking across healthcare, it could be worth scanning other specialised opportunities through the Simply Wall St screener for 6 healthcare AI stocks

    Kyowa Kirin’s share price has picked up on the back of stronger half year numbers, which can leave you wondering whether to act now or wait for a cheaper entry. So how does the current valuation stack up against those results?

    Price to Earnings of 16.8x for Kyowa Kirin: Is it justified?

    On the latest numbers, Kyowa Kirin trades on a P/E of 16.8x, which leaves the stock looking mixed when compared with both a fair value estimate and peers.

    The P/E ratio compares the current share price to earnings per share. For a profitable pharmaceutical company like Kyowa Kirin, it acts as a quick gauge of how much investors are paying for each unit of earnings.

    On one side, Kyowa Kirin screens as good value against an estimated fair P/E of 23.4x. This suggests the market is not fully pricing in its earnings profile based on that fair ratio model. On the other side, the stock looks expensive against a peer average P/E of 15.5x and the broader JP Pharmaceuticals industry average of 14.9x. This implies investors are already paying a premium relative to many competitors.

    Explore the SWS fair ratio for Kyowa Kirin

    Result: Price-to-Earnings of 16.8x (UNDERVALUED)

    However, you should still keep an eye on Kyowa Kirin’s relatively weak 5 year total return and the risks around its broad late stage drug pipeline execution.

    Find out about the key risks to this Kyowa Kirin narrative.

    Another View on Kyowa Kirin’s Valuation

    The P/E discussion paints Kyowa Kirin as undervalued, yet the SWS DCF model suggests a similar conclusion from a very different angle. At ¥2,602.5, the stock sits below an estimated future cash flow value of ¥3,569.33, which also points to undervaluation. Could the gap reflect caution around execution rather than the fundamentals themselves?

    Look into how the SWS DCF model arrives at its fair value.

    4151 Discounted Cash Flow as at Aug 2026
    4151 Discounted Cash Flow as at Aug 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kyowa Kirin for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 22 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Given the mixed signals around Kyowa Kirin’s valuation and recent results, it makes sense to review the details yourself and decide quickly where you stand. To see what investors are currently optimistic about, take a closer look at the 4 key rewards.

    Looking For More Investment Ideas Beyond Kyowa Kirin?

    If Kyowa Kirin has sharpened your focus, do not stop here. Fresh ideas across sectors can help keep a portfolio balanced and prepared for changing conditions.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.